TFR Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.52M Buy
5,074
+37
+0.7% +$16.4K 0.71% 39
2026
Q1
$2.25M Buy
5,037
+11
+0.2% +$5.13K 0.69% 44
2025
Q4
$2.28M Buy
5,026
+91
+2% +$39.2K 0.75% 33
2025
Q3
$1.93M Sell
4,935
-15
-0.3% -$6.27K 0.65% 48
2025
Q2
$2.2M Buy
4,950
+194
+4% +$89.4K 0.8% 35
2025
Q1
$2.31M Buy
4,756
+195
+4% +$90.9K 0.96% 27
2024
Q4
$1.84M Buy
+4,561
New +$2.11M 0.91% 35

Other funds holding VRTX

TFR Capital's VRTX Position: Q2 2026 in Review

TFR Capital increased its Vertex Pharmaceuticals (VRTX) stake by 0.73% in Q2 2026, buying an estimated $16.4K and bringing the position to 5,074 shares worth $2.52M. The position accounts for 0.71% of the portfolio, ranked #39.

TFR Capital first reported a position in VRTX in Q4 2024 and has held it in 7 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • TFR Capital held 5,074 shares of Vertex Pharmaceuticals worth $2.52M as of Q2 2026.
  • TFR Capital bought 37 Vertex Pharmaceuticals shares in Q2 2026, an estimated $16.4K.
  • Vertex Pharmaceuticals made up 0.71% of TFR Capital's portfolio in Q2 2026, its #39 holding.
  • TFR Capital first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on TFR Capital's 13F filing for Q2 2026, filed 6 Aug 2026.